HLS Therapeutics (OTCMKTS:HLTRF) Stock Price Down 1.1% – Time to Sell?

HLS Therapeutics Inc. (OTCMKTS:HLTRF)’s share price dropped 1.1% during trading on Thursday. The company traded as low as $2.79 and last traded at $2.79. 5,000 shares were traded during mid-day trading, an increase of 254% from the average daily volume of 1,413 shares. The stock had previously closed at $2.82.

Analyst Ratings Changes

Separately, Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

HLS Therapeutics Price Performance

The firm’s 50-day moving average is $2.83 and its 200-day moving average is $3.08.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines in Canada and the United States. The company concentrates on products that address significant medical needs, with an emphasis on central nervous system and cardiovascular therapies.

HLS has commercialized branded prescription medicines and specialty products through partnerships, licensing arrangements and acquired product rights. Its portfolio has included Clozaril (clozapine), a treatment used in schizophrenia, as well as other therapies marketed through specialty-care and hospital channels.